



The big Multiple Sclerosis data network

10th JOINT ACTRIMS-ECTRIMS CONGRESS 2026

CHRONOLOGICAL PROGRAMME SCHEDULE

Accepted contributions of MS Registries belonging to the Big Multiple Sclerosis Data (BMSD) Network:

- Czech MS Registry (ReMuS)
- Danish MS Registry (DMSR)
- French MS Registry (OFSEP)
- German MS Registry (GMSR)
- Italian MS Registry (RISM)
- MSBase
- Swedish MS Registry (SMSReg)

73		
TOTAL CONTRIBUTIONS		
16	42	15
ORAL PRESENTATIONS	POSTER SESSIONS	E-POSTERS

✦ DAY 1 — WEDNESDAY, 21 OCTOBER 2026

ORAL PRESENTATIONS — WEDNESDAY, 21 OCTOBER 2026

TYPE / CODE	TITLE, AUTHOR & REGISTRY	SESSION & TIME (GMT-4)
Oral (0083)	Subclinical MRI activity independently predicts the development of SPMS, PIRA and confirmed disability worsening in multiple sclerosis Author: Cristina Torres-Mora Registry: MSBase Registry	Free Communications Session 2, 21 Oct 2026, 11:20 AM-11:30 AM
Oral (0006)	Brain- versus Spinal Cord–Predominant Phenotypes in Multiple Sclerosis: Demographic Characteristics and Associations with Disability Progression in a Large Cohort with Brain and Whole Spinal Cord Imaging Author: Mathilde Liffra n Registry: French MS Registry (OFSEP)	Scientific Session 2, 21 Oct 2026, 11:57 AM - 12:04 PM
Oral (0082)	Disease-Transition Network Modeling of the Multiple Sclerosis Prodrome: A Danish Nationwide Study Author: Melinda Magyari Registry: Danish MS Registry (DMSR)	Free Communications Session 1, 21 Oct 2026, 12:10 PM-12:20 PM
Oral (0092)	Comparative Effectiveness of Ofatumumab vs Ocrelizumab in Relapsing Multiple Sclerosis : A Target Trial Emulation Using MSBase and OFSEP Author: Chao Zhu Registry: French MS Registry (OFSEP)	Scientific Session 3, 21 Oct 2026, 03:20 PM - 03:30 PM
Oral (0092)	Comparative Effectiveness of Ofatumumab vs Ocrelizumab in Relapsing Multiple Sclerosis: A	Free Communications Session 3, 21 Oct 2026, 3:20 PM-3:30 PM

	Target Trial Emulation Using MSBase and OFSEP Author: Chao Zhu Registry: MSBase Registry	
Oral (0093)	Effectiveness of Escalation vs. Early High-Efficacy Therapies on Progression Independent of Relapse Activity in Multiple Sclerosis: A Danish nationwide study Author: Eliza Viktoria Varju Registry: Danish MS Registry (DMSR)	Free Communications Session 3, 21 Oct 2026, 3:30 PM-3:40 PM
Oral (0094)	Emulation of a placebo-controlled natalizumab trial in multiple sclerosis: insights from AFFIRM and MSBase registry Author: Winston Dzau Registry: MSBase Registry	Free Communications Session 3, 21 Oct 2026, 3:40 PM-3:50 PM

POSTER SESSION — WEDNESDAY, 21 OCTOBER 2026

TYPE / CODE	TITLE, AUTHOR & REGISTRY	SESSION & TIME (GMT-4)
Poster (P0036)	Accelerating Diagnosis and Treatment in Pediatric Onset Multiple Sclerosis: 25 Years of Real-World Evidence from the Italian Multiple Sclerosis and Related Disorders Register Author: Pasquale Paletta Registry: Italian MS Registry (RISM)	Poster Session 1, 21 Oct 2026
Poster (P0044)	Familial risk of multiple sclerosis: A nationwide registry-based study in Denmark Author: Elisabeth Framke Registry: Danish MS Registry (DMSR)	Poster Session 1, 21 Oct 2026

Poster (P0081)	Personalized MS risk prediction for everyone: implementing the DAAE score in a Common Data Model Author: Gregor Fistravec Registry: Czech MS Registry (ReMuS)	Poster Session 1, 21 Oct 2026
Poster (P0151)	Air pollution and the risk of multiple sclerosis relapse risk in the Paris region: insights from the CONFISEP study Author: Edouard Januel Registry: French MS Registry (OFSEP)	Poster Session 1, 21 Oct 2026
Poster (P0207)	Measurement of Quantitative Susceptibility Mapping of the spinal cord in people with Multiple Sclerosis and Association With Clinical Disability Author: Anne Kerbrat Registry: French MS Registry (OFSEP)	Poster Session 1, 21 Oct 2026
Poster (P0243)	Impact of Multiple Sclerosis Disease-modifying Therapies on Chronic Lesion Tissue Expansion Author: Kayla Ward Registry: MSBase Registry	Poster Session 1, 21 Oct 2026
Poster (P0250)	Automated Detection of New Spinal Cord Lesions Between Two Longitudinal MRI Scans in people with MS could Improve Radiologists Sensitivity Author: Louis Padé Registry: French MS Registry (OFSEP)	Poster Session 1, 21 Oct 2026
Poster (P0256)	Cladribine Tablets Treatment after 4 years: Impact on MRI lesion accumulation Author: Marco Battaglini Registry: Czech MS Registry (ReMuS)	Poster Session 1, 21 Oct 2026
Poster (P0264)	Chronic Lesion Expansion as a Predictor of Disability Progression in Relapsing Multiple Sclerosis	Poster Session 1, 21 Oct 2026

Author: **Michael Hayes** | Registry:
MSBase Registry

Poster (P0307)	Data-Driven MRI Phenotypes in Multiple Sclerosis Author: Tomas Uher Registry: Czech MS Registry (ReMuS)	Poster Session 1, 21 Oct 2026
Poster (P0374)	Individualized treatment response in multiple sclerosis predicted with machine learning Author: Hassam Iqbal Registry: MSBase Registry	Poster Session 1, 21 Oct 2026
Poster (P0389)	Effect of Cladribine on Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis Author: Samuel Klistorner Registry: MSBase Registry	Poster Session 1, 21 Oct 2026
Poster (P0394)	Comparative Effectiveness of Initial Therapies in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis: a Multi-Arm Target Trial Emulation with Causal Mediation Analysis For Relapse Contribution Author: Antoine Gavoille Registry: French MS Registry (OFSEP)	Poster Session 1, 21 Oct 2026
Poster (P0407)	A Causal Effect of Early High-Efficacy Therapy Across Ages Author: Dagmawi Haile Registry: MSBase Registry	Poster Session 1, 21 Oct 2026
Poster (P0408)	Cladribine tablets in MS: Long-term management 4+ years post-initiation across age groups. Author: David Ellenberger Registry: German MS Registry (GMSR)	Poster Session 1, 21 Oct 2026
Poster (P0410)	Up to 3-Year Ponesimod Effectiveness and Treatment Patterns in 964 Patients With MS: A Czech National ReMuS Registry	Poster Session 1, 21 Oct 2026

	Analysis in the Multi-S1P Modulator Era Author: Dominika Stastna Registry: Czech MS Registry (ReMuS)	
Poster (P0413)	Post authorization drug safety monitoring using multiple sclerosis patient registries Author: Elena Flavia Mouresan Registry: Swedish MS Registry (SMSReg)	Poster Session 1, 21 Oct 2026
Poster (P0414)	Extension of the RIFUND-MS Target Trial Emulation to a Broader Real-World Population in the Swedish MS registry. Author: Elena Flavia Mouresan Registry: Swedish MS Registry (SMSReg)	Poster Session 1, 21 Oct 2026
Poster (P0418)	Real-World Treatment Patterns with Cladribine Tablets Beyond Year 5: Additional Treatment, Treatment Switching, and Treatment-Free Status in the CLADRISE Study from the Czech ReMuS Registry Author: Gregor Fistravec Registry: Czech MS Registry (ReMuS)	Poster Session 1, 21 Oct 2026
Poster (P0420)	Real-World Effectiveness and Safety of First-Line Ocrelizumab Treatment in Early-Stage Relapsing Multiple Sclerosis Author: Helmut Butzkueven Registry: MSBase Registry	Poster Session 1, 21 Oct 2026
Poster (P0433)	Ofatumumab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nation-Wide Cohort Study Author: Luigi Pontieri Registry: Danish MS Registry (DMSR)	Poster Session 1, 21 Oct 2026

Poster (P0441)	Age- and Sex-Specific Effects of Initial High-Efficacy Therapy Versus an Escalation Strategy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Author: Melinda Magyari Registry: Danish MS Registry (DMSR)	Poster Session 1, 21 Oct 2026
Poster (P0449)	Comparison of Semaglutide and Sodium-Glucose Cotransporter 2 inhibitors on disability accrual in patients with Multiple Sclerosis: a study on the Danish MS Register Author: Salvatore Iacono Registry: Danish MS Registry (DMSR)	Poster Session 1, 21 Oct 2026
Poster (P0454)	Incidence and Risk Factors for Pneumonia in a Prospective, Real-World, Multicentric Cohort of Multiple Sclerosis Patients Treated With Anti-CD20 Monoclonal Antibodies Author: Davide Quartana Registry: Italian MS Registry (RISM)	Poster Session 1, 21 Oct 2026
Poster (P0456)	MRI outperforms clinical predictors of disease activity after cladribine initiation in multiple sclerosis Author: Tomas Uher Registry: Czech MS Registry (ReMuS)	Poster Session 1, 21 Oct 2026
Poster (P1151)	Infections and Malignancies in Multiple Sclerosis: Meta-Analysis and Real-World Data From the Czech National ReMuS Registry Author: Dominika Stastna Registry: Czech MS Registry (ReMuS)	Poster Session 1, 21 Oct 2026

✦ DAY 2 — THURSDAY, 22 OCTOBER 2026

ORAL PRESENTATIONS — THURSDAY, 22 OCTOBER 2026

TYPE / CODE	TITLE, AUTHOR & REGISTRY	SESSION & TIME (GMT-4)
Oral (O100)	Risk of Inflammatory Bowel Disease Following Anti-CD20 Treatment in Multiple Sclerosis: A Population-Based Cohort Study Author: Peter Alping Registry: Swedish MS Registry (SMSReg)	Free Communications Session 5, 22 Oct 2026, 9:50 AM-10:00 AM
Oral (O104)	Profiling the long-term risk of Severe Adverse Events in a cohort of Multiple Sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study) Author: Damiano Paolicelli Registry: Italian MS Registry (RISM)	Free Communications Session 5, 22 Oct 2026, 10:30 AM-10:40 AM
Oral (O017)	Validation of the 2025ECTRIMS Consensus Recommendations on DMT Discontinuation: A Target Trial Emulation Using MSBase Author: Daniela Soares Régua Registry: MSBase Registry	Scientific Session 6, 22 Oct 2026, 11:50 AM - 11:57 AM
Oral (O018)	Older Age Predicts Relapse-Associated Worsening in Multiple Sclerosis Author: Yi Chao Foong Registry: MSBase Registry	Scientific Session 6, 22 Oct 2026, 11:57 AM - 12:04 PM
Oral (O020)	Exit Strategies after Anti-Cell Trafficking Therapies in Multiple Sclerosis Patients aged ≥50 years: a Target Trial Emulation Author: Jannis Müller Registry: MSBase Registry	Scientific Session 6, 22 Oct 2026, 12:11 PM - 12:18 PM

Oral (0036)	Serum GFAP and age accurately distinguish AQP4-IgG positive and double seronegative NMOSD from MOGAD after a recent attack Author: Manon Rival Registry: French MS Registry (OFSEP)	Scientific Session 10, 22 Oct 2026, 03:41 PM - 03:48 PM
--------------------	---	---

POSTER SESSION — THURSDAY, 22 OCTOBER 2026

TYPE / CODE	TITLE, AUTHOR & REGISTRY	SESSION & TIME (GMT-4)
Poster (P1059)	Prevalence and treatment of symptomatic sexual dysfunction in people with multiple sclerosis: 10-year real-world evidence from the German MS Register Author: David Ellenberger Registry: German MS Registry (GMSR)	Poster Session 2, 22 Oct 2026
Poster (P1091)	Education Expands the Window of Preserved Function in Multiple Sclerosis Author: Alessandro Cruciani Registry: Italian MS Registry (RISM)	Poster Session 2, 22 Oct 2026
Poster (P1093)	Improving long-term disability outcomes in multiple sclerosis over 30 years: A registry-based cohort analysis Author: David Ellenberger Registry: German MS Registry (GMSR)	Poster Session 2, 22 Oct 2026
Poster (P1099)	High-efficacy Therapy Controls Relapses More Effectively Than Progression Independent of Relapse Activity Author: Izanne Roos Registry: MSBase Registry	Poster Session 2, 22 Oct 2026
Poster (P1105)	Towards Prediction of Progression Independent of Relapses In Multiple Sclerosis by Integrating	Poster Session 2, 22 Oct 2026

Clinical Data and Patient-Reported Outcomes

Author: **Lars Forsberg** | Registry:
Swedish MS Registry (SMSReg)

Poster (P1106)	Exploring Large Language Models for Clinical Interpretation in Multiple Sclerosis Author: Lars Forsberg Registry: Swedish MS Registry (SMSReg)	Poster Session 2, 22 Oct 2026
Poster (P1113)	Severity of the Multiple Sclerosis Prodrome is Associated with Later Disability Author: Peter Alping Registry: Swedish MS Registry (SMSReg)	Poster Session 2, 22 Oct 2026
Poster (P1123)	Progression Independent Of Relapse Activity Is A Late Clinical Marker Of Disability Accumulation In Relapsing Multiple Sclerosis Author: Xanat Jazmín López Camaño Registry: MSBase Registry	Poster Session 2, 22 Oct 2026
Poster (P1125)	Preconception Use of Disease Modifying Therapy in Women with MS: A 25-Year Danish Nationwide Study Author: Agata Beczek Registry: Danish MS Registry (DMSR)	Poster Session 2, 22 Oct 2026
Poster (P1142)	Influence of Anovulation and Menopause on the Course of Multiple Sclerosis – the prospective LOTUS-MS Study Author: Simon Faissner Registry: German MS Registry (GMSR)	Poster Session 2, 22 Oct 2026
Poster (P1143)	Structural Brain Changes Across Pregnancy and the Postpartum Period in Women with Multiple Sclerosis Author: Vilija Jokubaitis Registry: MSBase Registry	Poster Session 2, 22 Oct 2026

Poster (P1385)	EBNA-1 IgG Defines an MS-Specific Immunological Signature Linking EBV Immunity to Intrathecal B-Cell Activity Author: Tomas Uher Registry: Czech MS Registry (ReMus)	Poster Session 2, 22 Oct 2026
Poster (P1449)	Comparison Of Siponimod And High-Efficacy Disease-Modifying Therapies In Secondary Progressive MS Author: Nathaniel Lizak Registry: MSBase Registry	Poster Session 2, 22 Oct 2026
Poster (P1451)	Escalation vs Induction Therapeutic Strategy in Patients With Late Onset Multiple Sclerosis Author: Nicolas Collongues Registry: French MS Registry (OFSEP)	Poster Session 2, 22 Oct 2026
Poster (P1460)	Optimal Responders to Autologous Hematopoietic Stem Cell Transplant Versus Natalizumab in Relapsing-remitting Multiple Sclerosis Author: Sifat Sharmin Registry: MSBase Registry	Poster Session 2, 22 Oct 2026
Poster (P1494)	From Incidental MRI Findings to Multiple Sclerosis: Do the 2024 McDonald Criteria Outperform the 2023 RIS Definition? Author: Christine Lebrun-Frenay Registry: French MS Registry (OFSEP)	Poster Session 2, 22 Oct 2026

◆ DAY 3 — FRIDAY, 23 OCTOBER 2026

ORAL PRESENTATIONS — FRIDAY, 23 OCTOBER 2026

TYPE / CODE	TITLE, AUTHOR & REGISTRY	SESSION & TIME (GMT-4)
Oral (0049)	Pregnancy-Associated Inflammatory Lesion Activity and Brain Volume Changes in Contemporary Women with Multiple Sclerosis Author: Vilija Jokubaitis Registry: MSBase Registry	Scientific Session 14, 23 Oct 2026, 9:05 AM -9:12 AM
Oral (0051)	Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis: A Swedish Registry-Based Cohort Study Author: Katharina Fink Registry: Swedish MS Registry (SMSReg)	Scientific Session 14, 23 Oct 2026, 9:19 AM -9:26 AM
Oral (0052)	Temporal Trends in Live Birth Rates and Treatment Discontinuation in Women with Multiple Sclerosis: A 30-Year MSBase Study Author: Emanuele D'Amico Registry: MSBase Registry	Scientific Session 14, 23 Oct 2026, 9:26 AM -9:33 AM

◆ ELECTRONIC POSTERS (E-POSTERS)

E-POSTERS EXHIBITION

TYPE / CODE	TITLE, AUTHOR & REGISTRY	SESSION & TIME (GMT-4)
ePoster (EP0039)	Evolving age at onset and diagnosis of progressive and relapsing MS in Sweden 2001-2021 Author: Astrid Pedersen Registry: Swedish MS Registry (SMSReg)	ePoster
ePoster (EP2020)	Multiple Sclerosis Without a Typical Attack? Multimodal Phenotyping of RIS and Subclinical MS Under the 2024 McDonald Criteria Author: Dominika Stastna Registry: Czech MS Registry (ReMuS)	ePoster
ePoster (EP2190)	Early Disease-Modifying Therapy Is Associated with Confirmed Disability Improvement After NMOSD Attacks Author: Karla Valdos Rodriguez Registry: MSBase Registry	ePoster
ePoster (EP2230)	Earlier diagnosis is associated with improved disability outcomes in Primary Progressive Multiple Sclerosis: impact of McDonald criteria revisions in a large real-world cohort Author: Pietro Iaffaldano Registry: Italian MS Registry (RISM)	ePoster
ePoster (EP2251)	Ovarian Reserve in Women with Multiple Sclerosis: A Cross-Sectional Study Author: Pierre Clavelou Registry: French MS Registry (OFSEP)	ePoster

ePoster (EP2375)	Should annual brain MRI monitoring be performed in all treated people with MS? Real-World detection rates of subclinical disease activity by treatment, duration, and age Author: Françoise Durand-Dubief Registry: French MS Registry (OFSEP)	ePoster
ePoster (EP2612)	Vigilance Is Key: Progressive Multifocal Leukoencephalopathy in the Czech MS Population, 2002–2026 Author: Dana Horakova Registry: Czech MS Registry (ReMuS)	ePoster
ePoster (EP2640)	Real-World Comparative Effectiveness and Persistence of Cladribine Tablets vs Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Updates from the MSBase Registry Author: Helmut Butzkueven Registry: MSBase Registry	ePoster
ePoster (EP2642)	Real-world Experience with Cladribine Tablets in the MSBase Registry 2026 Update Author: Helmut Butzkueven Registry: MSBase Registry	ePoster
ePoster (EP2651)	Real-World Persistence With Ofatumumab in Patients With Relapsing Form of MS in France: Interim Results From the ASTREOS Study Based on OFSEP Data (EDMUS Database) Author: Jonathan Ciron Registry: French MS Registry (OFSEP)	ePoster
ePoster (EP2687)	Clinico-Radiological Agreement Reveals Subtypes of Temporal Progression in MS: A Longitudinal Single-Center Study	ePoster

Author: **Natalia Komornikova** |
Registry: **Czech MS Registry (ReMuS)**

ePoster (EP2708)	Real World Effectiveness of Ofatumumab in Australian Adults with Relapsing MS: A Retrospective Analysis of the MSBase Registry Author: Anneke van der Walt Registry: MSBase Registry	ePoster
ePoster (EP2710)	Real-world relapses and disability outcomes in non-highly active relapsing multiple sclerosis patients treated with ofatumumab: an MSBase registry analysis Author: Tim Spelman Registry: MSBase Registry	ePoster
ePoster (EP2726)	Real-World Outcomes of Ofatumumab in Relapsing MS: EAFToS Part II, a Novel Study Linking MSGo with Other Real-World Clinical Data Sources Author: Anneke van der Walt Registry: MSBase Registry	ePoster
ePoster (EP2747)	European Mapping of Multiple Sclerosis Registries for the Evaluation of Safety Outcomes: A Scoping Review Author: Marco Salivetto Registry: Italian MS Registry (RISM)	ePoster

In 2026, the BMSD Network activities were supported by the unconditional sponsorship of

SANDOZ



The big Multiple Sclerosis data network

For the digital version of this leaflet, please visit the
dedicated page on the BMSD website:

<https://bigmsdata.org/>

